FDA Approves At-Home HPV Test, Boosting Cancer Screening Access

The U.S. Food and Drug Administration (FDA) has cleared a new at-home self-collection kit for Human Papillomavirus (HPV) testing. This development aims to broaden access to cervical cancer screening.

The Onclarity HPV Self-Collection Kit, developed by Waters Corporation, detects high-risk HPV genotypes. It is expected to be available in the coming months and will be covered by private insurance, Medicaid, and Medicare.

This new option follows updated cervical cancer screening guidelines from the Health Resources & Services Administration (HRSA) and a U. S.

Preventive Services Task Force (UPSTF) recommendation endorsing self-swab at-home tests. These guidelines support self-collection methods for individuals aged 30 and older.

At-home HPV testing methods are intended to reduce barriers to care, such as limited access to clinics or discomfort with traditional screening. This expansion of access is projected to improve early detection and reduce cervical cancer-related mortality, particularly among underserved populations.

Test results from the self-collected samples are sent to a designated healthcare professional for follow-up and treatment decisions.